April 22 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 ARISE TRIAL EVALUATING COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) AS AN ADJUNCTIVE TREATMENT TO ATYPICAL ANTIPSYCHOTICS IN ADULTS WITH SCHIZOPHRENIA
BRISTOL-MYERS SQUIBB CO - COBENFY DID NOT REACH STATISTICAL SIGNIFICANCE IN PHASE 3 TRIAL
BRISTOL-MYERS SQUIBB CO - COBENFY SAFETY AND TOLERABILITY CONSISTENT WITH PREVIOUS TRIALS
Source text: ID:nBw8K3lGVa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.